---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-013182"
form_type: "8-K"
ticker: null
cik: "0001044378"
company_name: "BIOCEPT INC"
filed_at: "2023-10-20T23:59:59+00:00"
generated_at: "2026-06-09T17:58:30.841516+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Biocept to be delisted from Nasdaq after Chapter 7 bankruptcy filing

## Summary
- Company filed Chapter 7 bankruptcy on October 13, 2023 in Delaware District Court.
- Nasdaq delisting notice received October 16, 2023 citing public interest and equity concerns.
- Trading of common stock and warrants suspended at market open on October 25, 2023.
- Company will not appeal the delisting determination.
- Caution that holders of common stock will likely experience a significant or total loss.

## SEC filing metadata
- accession: 0001654954-23-013182
- form_type: 8-K
- cik: 0001044378
- company_name: BIOCEPT INC
- filed_at: 2023-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1044378/000165495423013182/0001654954-23-013182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1044378/000165495423013182/biocept_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-013182
- JSON: https://secwatch.observer/filing/0001654954-23-013182.json
- Plain text: https://secwatch.observer/filing/0001654954-23-013182.txt

## Key facts
- Listing & Compliance Notices
  BIOCEPT INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: May 17, 2023, Staff also notified the Company that it failed to maintain a minimum of $2,500,000 in stockholders’ equity required for continued listing pursuant to Listing Rule 5550(b)(1), which deficiency serves as an additional and separate basis for delisting. The Staff letter indicates that the trading of the Company’s common stock and warrants will be suspended at the opening of business on October 25, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not i
  evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000165495423013182/0001654954-23-013182-index.htm
- Listing & Compliance Notices
  BIOCEPT INC received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Rules: 5101, 5110(b), IM-5101-1
  source text: October 16, 2023, the Company received a letter (“Delisting Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined that the Company’s securities will be delisted from Nasdaq pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, in connection with the filing of a voluntary case under Chapter 7 of Title 11 of the United States Bankruptcy Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on October 13, 202
  evidence_url: https://www.sec.gov/Archives/edgar/data/1044378/000165495423013182/0001654954-23-013182-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.